[(1R)-1-(naphthalen-1-yl)ethyl]({3-[3-(trifluoromethyl)phenyl]propyl})amine hydrochloride

• ChemBase ID: 70434
• Molecular Formular: C22H23ClF3N
• Molecular Mass: 393.8729296
• Monoisotopic Mass: 393.14711208
• SMILES: C(CCc1cc(ccc1)C(F)(F)F)N[C@H](C)c1cccc2ccccc12.Cl
• Canonical SMILES: C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F.Cl
• InChI: InChI=1S/C22H22F3N.ClH/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25;/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3;1H/t16-;/m1./s1
• InChIKey: QANQWUQOEJZMLL-PKLMIRHRSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: [(1R)-1-(naphthalen-1-yl)ethyl]({3-[3-(trifluoromethyl)phenyl]propyl})amine hydrochloride
• IUPAC Traditional name: cinacalcet hydrochloride
• Synonyms: (R)-N-(1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoro-methyl)phenyl)propan-1-amine hydrochloride; (αR)-α-Methyl-N-[3-[3-(trifluoromethyl)phenyl)propyl]-1-napthalenemethanamine Hydrochloride; (R)-N-(3-(3-(trifluoromethyl)phenyl)propyl)-1--(1-napthyl)ethylamine Hydrochloride; Cinacalcet Hydrochloride; Cinacalcet hydrochloride; Mimpara; Sensipar; AMG-073 HCl

Database IDs

• CAS Number: 364782-34-3
• PubChem SID: 162036152
• PubChem CID: 156418

CALCULATED PROPERTIES

• H Acceptors: 1
• H Donor: 1
• LogD (pH = 5.5): 3.042948
• LogD (pH = 7.4): 3.5335772
• Log P: 6.273198
• Molar Refractivity: 100.1173 cm^3
• Polarizability: 38.956448 Å^3
• Polar Surface Area: 12.03 Å^2
• Rotatable Bonds: 7
• Lipinski's Rule of Five: false

PROPERTIES

Physical Property

• Solubility: DMSO; Methanol
• Apperance: Off-White to Tan Solid
• Melting Point: 175-177°C

Safety Information

• Storage Condition: -20°C; -20°C Freezer
• Storage Warning: IRRITANT
• TSCA Listed: false

Product Information

• Purity: 95+%
• Salt Data: Hydrochloride

DETAILS

Selleck Chemicals - S1260

Research Area: Endocrinology
Biological Activity:
AMG-073 HCl (Cinacalcet hydrochloride) represents a new class of compounds for the treatment of hyperparathyroidism known as calcimimetics, which reduce parathyroid hormone (PTH) synthesis and secretion by increasing the sensitivity of the parathyroid calcium-sensing receptor (CaR) to extracellular calcium. The current study evaluates the efficacy and safety of AMG 073 when added to conventional treatment of secondary hyperparathyroidism in end-stage renal disease (ESRD). [1]

Toronto Research Chemicals - C441800

The (R) enantiomer of Cinacalcet. Used in clinical trial in secondary hyperparathyroidism.

REFERENCES

• http://www.rxlist.com/sensipar-drug.htm
• Franceschini N., et al.: Expert Opin. Invest. Drugs, 12, 1413 (2003)
• Block, G.A., et al.: N. Engl. J. Med. 350, 1516 (2003)